Contributions
Abstract: P1215
Type: Poster Sessions
Abstract Category: Therapy - Immunomodulation/Immunosuppression
Introduction: Dimethyl-fumarate (DMF) and Teriflunomide are approved oral disease modifying therapies (DMT) for relapsing-remitting multiple sclerosis (RRMS). Phase 3 trials established these agents as effective and generally well tolerated, though comparative efficacy and discontinuation remain unknown.
Objectives: To assess real-world efficacy and discontinuation of DMF and Teriflunomide in patients with RRMS.
Methods: This retrospective observational cohort study was lead in a French administrative region (Auvergne) between March 2014 and July 2017. Both patients followed by private neurologists or hospital neurologists were included. Efficacy and tolerance of the two treatments were assessed and compared using multivariate analysis, taking into account MS duration, annualized relapse rate (ARR) at treatment initiation, EDSS at treatment initiation, type of prescriber and tobacco use.
Results: We identified 189 DMF-treated and 157 Teriflunomide-treated patients in the region treated for 22 ± 10 months. After correction for confounders, DMF reduced more efficiently the ARR at 2 years compared to Teriflunomide (0.06 vs 0.21; p< 0.05). DMF-treated patients had more clinical and biological adverse events (AE). These AE led to more treatment discontinuation (28% vs 12%; p=0.03).
Conclusions: In this retrospective cohort study, DMF demonstrated significantly higher efficacy over 2 years versus Teriflunomide. Teriflunomide tolerance was better.
Disclosure: S Condé: Non-financial support from Biogen Idec, Bristol-Myers Squibb, Effik, Genzyme, GSK, LFB, Merck Serono, Novartis, Pfizer, Roche, UCB Pharma and Teva.
X Moisset: Non-financial support from Biogen Idec, Boehringer Ingelheim, Bristol-Myers Squibb, Effik, Genzyme, GSK, Icomed, Merck, Mylan, Novartis, Pascaleo, Roche, Sanofi and Teva ; Honoraria and consulting fees from Merck Serono and Teva.
B Pereira: Nothing to disclose.
M Zuel: Non-financial support from Biogen Idec, Bristol-Myers Squibb, Eisai, Elia Medical, Genzyme, Pfizer and Teva.
R Colamarino: Honoraria and consulting fees from Genzyme, Merck, Novartis, Roche and Sanofi, not relating to the submitted work.
M Maillet-Vioud: Honoraria and consulting fees from A&A, Genzyme, IMS Medical Radar, Inter-view Partners, PSL Group Service, and Zeste Research, not relating to the submitted work ; Research supports from Quintiles Benefit.
M Lauxerois: Non-financial support from A&A, Aguettant, Biogen Idec, Bristol-Myers Squibb, Cyberonics, Eisai, Grunenthal, GSK, Medtronic, Novartis, Pfizer, Roche, Sanofi,Teva and UCB Pharma ; Honoraria and consulting fees from Biogen Idec and Merck Serono, not relating to the submitted work.
F Taithe: Non-finanical support from Bayer Healthcare, Biogen Idec, Effik, Exafield, Genzyme, LFB, Merck Serono, Novartis, Pascaleo, Pfizer, Roche, Teva and UCB Pharma ; Honoraria and consulting fees from Genzyme, Merck and Novartis, not relating to the submitted work.
P Clavelou: Honoraria and consulting fees from Eisai, Genzyme, Medday, Merck Serono, Novartis, PPD France, Roche and Teva, not relating to the submitted work ; Research supports from Biogen Idec, Merck and Novartis, not relating to the submitted work.
Abstract: P1215
Type: Poster Sessions
Abstract Category: Therapy - Immunomodulation/Immunosuppression
Introduction: Dimethyl-fumarate (DMF) and Teriflunomide are approved oral disease modifying therapies (DMT) for relapsing-remitting multiple sclerosis (RRMS). Phase 3 trials established these agents as effective and generally well tolerated, though comparative efficacy and discontinuation remain unknown.
Objectives: To assess real-world efficacy and discontinuation of DMF and Teriflunomide in patients with RRMS.
Methods: This retrospective observational cohort study was lead in a French administrative region (Auvergne) between March 2014 and July 2017. Both patients followed by private neurologists or hospital neurologists were included. Efficacy and tolerance of the two treatments were assessed and compared using multivariate analysis, taking into account MS duration, annualized relapse rate (ARR) at treatment initiation, EDSS at treatment initiation, type of prescriber and tobacco use.
Results: We identified 189 DMF-treated and 157 Teriflunomide-treated patients in the region treated for 22 ± 10 months. After correction for confounders, DMF reduced more efficiently the ARR at 2 years compared to Teriflunomide (0.06 vs 0.21; p< 0.05). DMF-treated patients had more clinical and biological adverse events (AE). These AE led to more treatment discontinuation (28% vs 12%; p=0.03).
Conclusions: In this retrospective cohort study, DMF demonstrated significantly higher efficacy over 2 years versus Teriflunomide. Teriflunomide tolerance was better.
Disclosure: S Condé: Non-financial support from Biogen Idec, Bristol-Myers Squibb, Effik, Genzyme, GSK, LFB, Merck Serono, Novartis, Pfizer, Roche, UCB Pharma and Teva.
X Moisset: Non-financial support from Biogen Idec, Boehringer Ingelheim, Bristol-Myers Squibb, Effik, Genzyme, GSK, Icomed, Merck, Mylan, Novartis, Pascaleo, Roche, Sanofi and Teva ; Honoraria and consulting fees from Merck Serono and Teva.
B Pereira: Nothing to disclose.
M Zuel: Non-financial support from Biogen Idec, Bristol-Myers Squibb, Eisai, Elia Medical, Genzyme, Pfizer and Teva.
R Colamarino: Honoraria and consulting fees from Genzyme, Merck, Novartis, Roche and Sanofi, not relating to the submitted work.
M Maillet-Vioud: Honoraria and consulting fees from A&A, Genzyme, IMS Medical Radar, Inter-view Partners, PSL Group Service, and Zeste Research, not relating to the submitted work ; Research supports from Quintiles Benefit.
M Lauxerois: Non-financial support from A&A, Aguettant, Biogen Idec, Bristol-Myers Squibb, Cyberonics, Eisai, Grunenthal, GSK, Medtronic, Novartis, Pfizer, Roche, Sanofi,Teva and UCB Pharma ; Honoraria and consulting fees from Biogen Idec and Merck Serono, not relating to the submitted work.
F Taithe: Non-finanical support from Bayer Healthcare, Biogen Idec, Effik, Exafield, Genzyme, LFB, Merck Serono, Novartis, Pascaleo, Pfizer, Roche, Teva and UCB Pharma ; Honoraria and consulting fees from Genzyme, Merck and Novartis, not relating to the submitted work.
P Clavelou: Honoraria and consulting fees from Eisai, Genzyme, Medday, Merck Serono, Novartis, PPD France, Roche and Teva, not relating to the submitted work ; Research supports from Biogen Idec, Merck and Novartis, not relating to the submitted work.